Compare ADMA Biologics Inc (ADMA) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs NextEra Energy, Inc. — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while NextEra Energy, Inc. trades at $85.66 (market cap $176.68B). The key difference: NextEra Energy, Inc. is far larger — about 81× ADMA Biologics Inc's market cap, and NextEra Energy, Inc. pays a 2.94% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | NEE | |
|---|---|---|
Market Cap | $2.18B | $176.68B |
Sector | Health | Utilities |
52-Week High | $20.38 | $97.88 |
52-Week Low | $7.60 | $69.77 |
Enterprise Value | $2.25B | $284.01B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
NextEra Energy (NEE) trades at $84.65, showing minimal daily movement with a 0.06% gain. The stock is in a bearish technical phase, with support at $84 and resistance at $86. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 missed. The company benefits from strong AI-driven power demand, highlighted by a $100 billion data center project in Kentucky announced on July 29, 2026 (Reuters).
NEE offers solid fundamentals with a 32.4% net income margin and 17.23% ROE, but faces risks from high debt levels and capital expenditures. Analysts are bullish with a $101.17 consensus price target, implying 19% upside. Key opportunities include AI infrastructure growth, while risks involve execution on large projects and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
